Chabner BA, Roberts TG Jr. Timeline: chemotherapy and the war on cancer. Nat Rev Cancer. 2005;5:65–72.
Article
CAS
PubMed
Google Scholar
Izar B, Rotow J, Gainor J, Clark J, Chabner B. Pharmacokinetics, clinical indications, and resistance mechanisms in molecular targeted therapies in cancer. Pharmacol Rev. 2013;65:1351–95.
Article
CAS
PubMed
Google Scholar
Schiavon G, Smith IE. Endocrine therapy for advanced/metastatic breast cancer. Hematol Oncol Clin North Am. 2013;27:715–36.
Article
PubMed
Google Scholar
Zhang J, Yang PL, Cray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer. 2009;9:28–39.
Article
PubMed
Google Scholar
Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapy. Nat Rev Drug Discov. 2010;9:767–74.
Article
CAS
PubMed
Google Scholar
Gibert LA, Hemann MT. Chemotherapeutic resistance: surviving stressful situation. Cancer Res. 2011;71:5062–6.
Article
Google Scholar
Trela E, Glowacki S, Blasiak J. Therapy of chronic myeloid leukemia: twilight of the imatinib era? IRSN Oncol. 2014;2014:596483.
Google Scholar
Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib resistant gastrointestinal stromal tumor. J Clin Oncol. 2008;26:5352–9.
Article
PubMed Central
CAS
PubMed
Google Scholar
Mahipal A, Kothari N, Gupta S. Epidermal Growth factor receptor inhibitors: coming of age. Cancer Control. 2014;21:74–9.
PubMed
Google Scholar
Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 2003;21:2787–99.
Article
CAS
PubMed
Google Scholar
Chong CR, Jänne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med. 2013;19:1389–400.
Article
PubMed Central
CAS
PubMed
Google Scholar
Becker K, Xu Y. Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutation. World J Clin Oncol. 2014;5:560–7.
Article
PubMed Central
PubMed
Google Scholar
Vincenzi B, Schiavon G, Silletta M, Santini D, Tonini G. The biological properties of cetuximab. Crit Rev Oncol Hematol. 2008;68:93–106.
Article
PubMed
Google Scholar
Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med. 2010;363:1734–9.
Article
CAS
PubMed
Google Scholar
Spaans JN, Goss GD. Trials to overcome drug resistance to EGFR and ALK targeted therapies—past, present, and future. Front Oncol. 2014;4:233.
PubMed Central
PubMed
Google Scholar
Scaltriti M, Rojo F, Ocaña A, Anido J, Guzman M, Cortes J, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst. 2007;99:628–38.
Article
CAS
PubMed
Google Scholar
Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol. 2010;28:1138–44.
Article
CAS
PubMed
Google Scholar
Marques I, Araújo A, de Mello RA. Anti-angiogenic therapies for metastatic colorectal cancer: current and future perspectives. World J Gastroenterol. 2013;19:7955–71.
Article
PubMed Central
PubMed
Google Scholar
Tejpar S, Prenen H, Mazzone M. Overcoming resistance to antiangiogenic therapies. Oncologist. 2012;17:1039–50.
Article
PubMed Central
CAS
PubMed
Google Scholar
Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, Heath AN, et al. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci USA. 2012;109:2784–9.
Article
PubMed Central
CAS
PubMed
Google Scholar
Würth R, Barbieri F, Florio T. New molecules and old drugs as emerging approaches to selectively target human glioblastoma cancer stem cells. Biomed Res Int. 2014;2014:126586.
Article
PubMed Central
PubMed
Google Scholar
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–54.
Article
CAS
PubMed
Google Scholar
Jarkowski A 3rd, Khushalani NI. BRAF and beyond: tailoring strategies for the individual melanoma patient. J Carcinog. 2014;13:1–12.
Article
PubMed Central
CAS
PubMed
Google Scholar
Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011;29:3085–96.
Article
PubMed Central
CAS
PubMed
Google Scholar
Druker BJ. Perspectives on development of imatinib and the future of cancer. Nat Med. 2009;15:1149–52.
Article
CAS
PubMed
Google Scholar
Lydon N. Attacking cancer at its foundation. Nat Med. 2009;15:1153–7.
Article
CAS
PubMed
Google Scholar
Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell. 2014;25:282–303.
Article
PubMed Central
CAS
PubMed
Google Scholar
Gradishar WJ. Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab. Ann Oncol. 2013;24:2492–500.
Article
CAS
PubMed
Google Scholar
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–84.
Article
CAS
PubMed
Google Scholar
Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365:1273–83.
Article
PubMed Central
CAS
PubMed
Google Scholar
Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182–6.
Article
CAS
PubMed
Google Scholar
Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005;333:328–35.
Article
CAS
PubMed
Google Scholar
Chen D, Bhat-Nakshatri P, Goswami C, Badve S, Nakshatri H. ANTXR1, a stem cell-enriched functional biomarker, connects collagen signaling to cancer stem-like cells and metastasis in breast cancer. Cancer Res. 2013;73:5821–33.
Article
PubMed Central
CAS
PubMed
Google Scholar
Goel G, Sun W. Cancer immunotherapy in clinical practice—the past, present, and future. Chin J Cancer. 2014;33:445–57.
Article
PubMed Central
CAS
PubMed
Google Scholar
Gottesman MM, Ling V. The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett. 2006;580:998–1009.
Article
CAS
PubMed
Google Scholar
Beckman RA, Chen C. New evidence-based adaptive clinical trial methods for optimally integrating predictive biomarkers into oncology clinical development programs. Chin J Cancer. 2013;32:233–41.
Article
PubMed Central
CAS
PubMed
Google Scholar
Huang D, Ding Y, Zhou M, Rini BI, Petillo D, Qian CN, et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res. 2010;70:1063–71.
Article
PubMed Central
CAS
PubMed
Google Scholar
Chen D, Goswami CP, Burnett RM, Anjanappa M, Bhat-Nakshatri P, Muller W, et al. Cancer affects microRNA expression, release, and function in cardiac and skeletal muscle. Cancer Res. 2014;74:4270–81.
Article
PubMed Central
CAS
PubMed
Google Scholar